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Systemic Lupus Erythematosus (SLE) is an autoimmune disorder characterized by excessive production of a variety of
autoantibodies and a wide range of clinical manifestations. Pathogenesis of SLE is complex and not fully understood. There is
however evidence that B and T cells are critical to the development of disease, and that T cell-derived cytokines are involved in
the SLE-associated inﬂammatory response. One such cytokine seems to be interleukin (IL)-21, the latest identiﬁed member of the
γ-chain-related cytokine family. IL-21 has an important role in the control of the growth, survival, diﬀerentiation, and function
of both T and B cells, and excessive production of IL-21 has been associated with the development of multiple immune-mediated
diseases. Here we review data supporting the involvement of IL-21 in the pathogenesis of SLE.
1.Introduction
Systemic lupus erythematosus (SLE) is a chronic systemic
autoimmune disease with considerable heterogeneity in
clinicalmanifestationsanddiseasecourse[1].Theetiologyof
SLEremainsunknown,butevidencesuggeststhatSLEresults
from the interaction of genetic and environmental factors
that ultimately promote an abnormal immune response
leading to the organ damage [1]. Dysregulation of various
components of the immune system can be seen at diﬀerent
stages of SLE development, but hyperactivity of B cells
with excessive production of multiple autoantibodies is
perhaps the major immunological stigmata of SLE [2, 3].
The pathogenic role of B cells in SLE is not however strictly
linked to the secretion of autoantibodies. B cells can have
potent antigen presentation capacity, and they regulate and
organize inﬂammatory responses [4]. Indeed, studies in
murine models of SLE have shown that B cells are critical
to the development of disease even when they are unable
to secrete autoantibodies [5, 6]. Moreover, studies in human
SLE showed that the clinical response obtained by treatment
of patients with rituximab, a B cell depleting anti-CD20
antibody, preceded autoantibody decline, thus supporting
the autoantibody-independent role of B cells in SLE process
[7].
A more detailed analysis of molecular mechanisms
underlying the SLE-associated tissue damaging-immune
response revealed that interactions between T and B cells
are essential in the development of this disease and that
cytokines are key mediators of this interplay [8]. However,
because of the redundant functions of cytokines, a major
challenge for scientists is to identify key molecule(s) which
can profoundly alter the outcome of SLE-associated inﬂam-
matory response. Here we discuss whether interleukin (IL)-
21 is worthy of this description.
2.IL-21-Producing Cells and Biological Effects
o fIL -2 1o nBandTL ym p h oc yt e s
Although IL-21 was initially considered as a cytokine pro-
duced by activated peripheral blood T cells [9], it is now
known that it can be synthesized by a range of diﬀerentiated
CD4+ T helper (Th) cells [10]. Studies in mice have shown
that IL-21 is synthesized exclusively by polarized Th17 cells,
while in human, IL-21 can also be made by Th1 cells [11–
16]. Activated NKT cells are another cell source of IL-212 Journal of Biomedicine and Biotechnology
[17]. More recently, it has been shown that IL-21 is also
produced by a subset of CD4+ T cells, which are involved in
germinal center (GC) formation and function, and denoted
T follicular helper cells (TFH cells) [18, 19]. TFH cells
expresshighlevelsofthechemokinereceptorchemokine(C–
X–Cmotif)receptor5(CXCR5),whichallowsthemtohome
to and be retained by the lymphoid follicle, where contact
with antigen-primed B cells promotes B cell proliferation,
isotype switching, and somatic mutation of the Ig repertoire
[20, 21]. CD8+ T cells do not normally produce IL-21.
However, these cells can synthesize IL-21 if deleted of
speciﬁc transcription factors, such as T-bet and eomesoder-
min, and infected with lymphocytic choriomeningitis virus
[22].
IL-21 activity is mediated by a heterodimeric receptor,
formed by the γ-chain subunit (shared with IL-2, IL-4, IL-7,
IL-9,IL-13,andIL-15receptors)anditsownuniquereceptor
(designatedIL-21R)[23,24].BindingofIL-21tothereceptor
leads to the activation of the Janus-kinase-family proteins
(JAK 1 and JAK 3) and signal transducer and activator of
transcription (STAT) 1 and STAT3 and, to a lesser degree,
STAT4 and STAT5 [10]. IL-21 also activates members of
the mitogen-activated protein kinase (MAPK) family such
as extracellular signal-regulated protein kinases (ERK) 1/2
in neoplastic cell, epithelial cells, and monocytes [25, 26].
Strictlylinkedtotheactivationofsuchintracellularpathways
is the ability of IL-21 to regulate the functional activity of
various immune and non-immune cell types [10]. Here we
highlight some of the biological eﬀects of IL-21 on B and T
cells, because of the pathogenic role of these cells in SLE. For
a detailed description of the regulatory functions of IL-21 on
both immune and non-immune cells, the reader is directed
towards recent reviews [10, 23, 24, 27].
IL-21 increases B cell proliferation after activation via
the B cell receptor plus T cell-derived costimulatory signals
[28, 29]. In contrast, IL-21 delivers proapoptotic signals to
primary B cells and B cells that are activated with anti-
IgM or toll-like receptors ligands [30, 31]. In cultures of
CD40-stimulated human B cells, the proliferative eﬀect of
IL-21 is dependent on Stat1 and Stat3 activation [32].
In vitro, stimulation of both murine and human B cells
with IL-21 induces the plasma-cell-associated transcription
factor B-lymphocyte-induced maturation protein 1, now
termed PR domain containing 1, and subsequent plasma
cell diﬀerentiation as well as the production of isotype-
switched immunoglobulins (i.e., IgG, IgM, and IgA) [28, 29,
33]. Importantly, the IL-21-driven generation of memory B
cells and plasma cells relies on Stat3, because IL-21 fails to
promote the diﬀerentiation of Ig-secreting cells in cultures
of na¨ ıve B cells isolated from patients with inactivating
mutations in Stat3 [32]. Using a well-established model of
Bc e l ld i ﬀerentiation, Avery et al. have also shown that the
hen egg lysozyme-speciﬁc response of IL-21R-null B cells is
diminished compared with wild-type B cells, as indicated
by the marked reduction in the number of antigen-speciﬁc
plasma cells and production of IgM and IgG [32]. Overall,
these results suggest that IL-21 and Stat3 play a crucial
role in initiating and/or maintaining serological immunity
by generating antigen-speciﬁc eﬀector B cells from na¨ ıve
precursors. By contrast, Stat3 does not seem to be necessary
for the IL-21-driven isotype switching to IgG [32].
IL-21 is also an important regulator of T cell functions.
IL-21 enhances the proliferation of anti-CD3-stimulated
T cells and acts in concert with other common γ-chain-
dependent cytokines to enhance the growth of CD4+ T
cells [10, 24]. However, IL-21 regulates diﬀerently the
diﬀerentiation and/or maintenance of polarized Th cells
depending on the species. Studies in mice revealed that IL-21
can expand either Th2 or Th17 cell responses and inhibit the
synthesis of interferon (IFN)-γ [11, 12, 34–36]. By contrast,
in populations of human peripheral blood or mucosal T
cells that are preactivated with anti-CD3, IL-21 enhances
the expression/activation of transcription factors that drive
Th1 cell diﬀerentiation (i.e., T-bet, Stat4) [14, 37]. IL-21
stimulates the proliferation of CD8+ T cells and synergizes
with IL-15 and IL-7 in promoting CD8+ T cell expansion
[38–40].
IL-21 seems to have an autocrine role for proper TFH
development. Studies in IL-21-deﬁcient mice showed that
CXCR5 surface expression on CD4+ T cells is greatly
reduced after immunization with a T-cell-dependent anti-
gen, and that IL-21R expression is signiﬁcantly higher on
CXCR5+CD4+ than on CXCR5–CD4+ T cells [19]. GC
developmentisimpairedinmicedeﬁcientforIL-21signaling
[41]. Adoptive transfer of wild-type CD4+ T cells into IL-
21R-null recipients followed by immunization rescues GC
formation and partially rescues Ig production [19].
3. Role of IL-21 inMurineModels of SLE
The fact that IL-21 controls the pool of memory B cells
and promotes diﬀerentiation of B cells into plasma cells
suggests that a deregulated IL-21 activity may contribute
to the development of autoimmune diseases. So, many
researchers have evaluated the contribution of IL-21 in the
pathogenesis of murine models of SLE. Studies from various
laboratories have been performed in BXSB.B6-Yaa+/J mice.
These strains result from a cross between a C57BL/6 female
and an SB/Le male, and the male oﬀspring of the cross had
a 50% mortality rate at 6 months of age [42]. The mice
display many of the symptoms common to SLE, includ-
ing lymphadenopathy, splenomegaly, hypergammaglobu-
linemia, and severe immune complex–mediated glomeru-
lonephritis [42]. Females of the strain, however, only display
a chronic syndrome. Subsequent studies have veriﬁed that
thedisorderisnotgonadalhormonallydrivenbutisY-linked
[42]. Analysis of multiple genes in splenocytes taken from
these mice revealed a marked age-dependent increase in the
levels of IL-21 mRNA as compared to wild-type mice [33].
Corresponding to the increase in IL-21 mRNA, serum levels
of IL-21, IgG1, and IgG3 were increased in BXSB.B6-Yaa+/J
mice [33]. Importantly, IL-21R-deﬁcient BXSB-Yaa+/J mice
show none of the abnormalities characteristic of SLE, thus
supporting the key role of IL-21 in the accumulation of
plasmacellsandproductionofautoantibodies.Inthismodel,
the excessive IL-21 production did not derive from TFH
cells, but rather from an extrafollicular population of ICOS+
CD4+ T cells [43].Journal of Biomedicine and Biotechnology 3
Further support to the pathogenic role of IL-21 in this
model of SLE was provided by preclinical studies showing
that administration of IL-21R/Fc, a fusion protein neutral-
izing IL-21, to BXSB.B6-Yaa+ mice results in a decreased
production of IL-21, diminished lymphocyte activation, and
reduced circulating IgG1 levels [44]. Proteinuria is also
reduced in treated mice, but the therapy does not prevent
the symptoms of SLE [44]. Moreover, follow-up studies
showed that the IL-21 contribution to SLE-like phenotype in
BXSB-Yaa mice is variable within the time course of disease
progression, because blockade of IL-21 activity in the early
phase is deleterious, whereas later in the time course it is
advantageous [44]. The reason why the blocking IL-21R/Fc
regulates diﬀerently the pathogenic inﬂammatory response
in BXSB-Yaa mice remains unknown. In this context, it is
noteworthy that IL-21 can exert both inﬂammatory and
anti-inﬂammatory eﬀects, the latter linked to the induc-
tion of IL-10, a counter-regulatory cytokine expressed at
high levels both in BXSB-Yaa mice and in human SLE
patients [33, 45–47]. Therefore, blockade of IL-21 with IL-
21R/Fc might inhibit IL-10 expression, thus exacerbating
the severity of SLE symptoms in the early phase of the
disease.
Studies in MRL-Faslpr mouse, another model of SLE,
showed that blockade of IL-21 with IL-21R/Fc signiﬁcantly
reduced proteinuria, lymphadenopathy, skin lesions, circu-
lating autoantibodies, and IgG1 and IgG2a [48]. In addi-
tion, MRL-Faslpr mice treated with anti IL-21R/Fc showed
reduced levels of glomerular IgG deposits in the kidney
and no thickening in glomerular basement membranes
by histological evaluation [48]. IL-21R/Fc treatment also
reduced the number of splenic T lymphocytes and B cells
antibodies production [48]. In the MRL-Faslpr mouse, IL-21
is primarily made by an extrafollicular population of ICOS-
expressing CD4+ T cells that exhibits reduced expression of
P-selectin glycoprotein ligand 1 but is able to produce IL-4
and IFN-γ [49].
Evidence for the pathogenic role of IL-21 in SLE also
comes from studies in the sanroque mouse strain, in which a
mutation in the RING-type ubiquitin ligase protein family
member, roquin, results in the accumulation of excessive
numbers of both GC and TFH cells with high levels of ICOS,
excessiveIL-21production, andsevereSLE-like autoimmune
phenotype [50]. Lupus-like symptoms are dependent on
enhancedGCformationastheycouldbereducedbydeletion
of even one allele of the BCL6 gene [51]. However, TFH
formation in this model seems to be dependent on ICOS
rather than IL-21 [51].
A subpopulation of B-1 cells expressing the programmed
death ligand 2 (termed L2pB-1 cells) has been shown to be
enriched for autoreactive immunoglobulin, to be potent in
antigenpresentation,andtobefullyabletofacilitateTh1and
Th17 cell diﬀerentiation. L2pB1 cells are found in increased
n u m b e r si nt h ep e r i p h e r yo fm i c ew i t hS L Ea n ds u c ha n
increase correlates with anti-DNA antibody levels. This well
ﬁts with the demonstration that L2pB-1 cells secrete high
levels of autoantibodies, such as dsDNA-reactive antibodies,
and can undergo isotype switch and generate IgG1 and
IgG2b in the presence of IL-21 [52].
4.IL-21 inHumanSLE
LittleisknownabouttheroleofIL-21inhumanSLE.Plasma
levels of IL-21 are signiﬁcantly higher in SLE patients than in
healthy controls, but IL-21 levels do not seem to correlate
with SLE activity [53]. We have recently shown that IL-21
mRNA expression is enhanced in skin biopsies taken from
individuals with SLE in comparison to normal controls, even
though this increase is less pronounced than that seen in
lesional skin of patients with psoriasis [54]. In patients with
SLE, IL-21R is under-repressed on total, na¨ ıve, and memory
B cells, and on plasmablasts, compared to controls [55].
Reduced levels of IL-21R are associated with nephritis and
a high titer of anti-double-stranded DNA antibodies in the
serum [55]. By contrast, blood T cells of SLE patients exhibit
normal levels of IL-21R [53].
Recent genome-wide association (GWA) studies have
shown that single nucleotide polymorphisms (SNPs) in the
chromosome 4q27 region containing IL-2 and IL-21 are
associated with chronic inﬂammatory disorders, including
inﬂammatory bowel disease (IBD), celiac disease, psoriasis,
diabetes, rheumatoid arthritis, asthma, and SLE, suggesting
a common genetic background for these diseases [56–62].
With regard to SLE, a ﬁrst study genotyped three SNPs in the
IL-21 gene in more than 1300 patients with SLE and controls
[62]. Two out of the three SNPs (rs907715 and rs2221903)
were signiﬁcantly associated with SLE [62]. Stratiﬁcation by
race revealed that this genetic association was found more in
European-American than in African-American SLE patients
[62]. The functional consequences of the IL-21 SNPs remain
unknown. The fact that both associated SNPs are located
within intronal regions of the IL-21 gene suggests however
the possibility that they can inﬂuence IL-21 production [62].
Another GWA study analyzed 17 SNPs in the IL-21R gene in
2 independent, ethnically divergent populations (European
and Hispanic) of SLE patients and controls [63]. A genetic
association between rs3093301 (A/G) and SLE was found
in both the European-derived and Hispanic cohorts [63].
Moreover, the lupus-risk allele was signiﬁcantly associated
with the presence of malar rash but not other symptoms or
signs of SLE [63].
5. Conclusions
The involvement of IL-21 in the pathogenic mechanisms
causing human SLE remains to be demonstrated. However,
both the ability of this cytokine to regulate in vitro and in
vivo immunological pathways that are relevant in SLE and
the evidence obtained in murine models of SLE suggest that
IL-21 could play an important role in the production of
pathogenic autoantibodies and end-organ damage in this
disease. Therefore, it is tempting to speculate that inhibitors
of IL-21 could be useful to attenuate lupus-related clinical
manifestations. However, in designing such clinical interven-
tions for blocking IL-21 one should take into consideration
not only the advantageous eﬀects but also the risk of
potentialanddeleteriousconsequencesforthehost.Infact,it
is well-known that, at least under speciﬁc circumstances, IL-
21 can also exert anti-inﬂammatory actions due to its ability4 Journal of Biomedicine and Biotechnology
to inhibit dendritic cell maturation and stimulate IL-10
production[45,64].Inthiscontext,itisalsonoteworthythat
IL-21 may stimulate immune responses against tumor cells
and promote CD8+ T cell responses against viruses [65–68].
Therefore, if so, blockade of IL-21 function could attenuate
antineoplastic immunity and wake worse the course of viral
infections.
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